LOTEPREDNOL ETABONATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTEPREDNOL ETABONATE (LOTEPREDNOL ETABONATE).
Corticosteroid with high glucocorticoid receptor affinity; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
| Metabolism | Hydrolyzed to inactive metabolites (loteprednol) by esterases in ocular tissues; minimal systemic metabolism. |
| Excretion | Primarily hepatic metabolism; metabolites excreted in urine (approximately 80% as inactive metabolites) and feces (15-20%). Less than 1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is 2.2-4.3 hours; clinical context: supports twice-daily dosing in ophthalmic use, with minimal systemic accumulation. |
| Protein binding | Approximately 70-90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Apparent volume of distribution is 2.6-3.8 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Ophthalmic: negligible systemic bioavailability (<1%) due to low corneal permeability and rapid hepatic first-pass metabolism of the small absorbed fraction. |
| Onset of Action | Topical ophthalmic: Onset of anti-inflammatory effect occurs within 30-60 minutes after instillation. |
| Duration of Action | Duration of anti-inflammatory effect lasts 12-24 hours after ophthalmic administration; clinical note: effects persist longer than plasma levels due to tissue binding. |
0.5% ophthalmic suspension: 1-2 drops into affected eye(s) four times daily. In severe cases, may be increased to 1-2 drops every hour during the first week, then taper.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. Not systemically absorbed to a significant extent. |
| Liver impairment | No dosage adjustment required for hepatic impairment. Not systemically absorbed to a significant extent. |
| Pediatric use | Children ≥1 year: 1-2 drops into affected eye(s) four times daily. For severe inflammation, may be increased to 1-2 drops every hour initially, then taper. Use lowest effective dose and duration. |
| Geriatric use | No specific dose adjustment required. Use with caution due to increased risk of intraocular pressure elevation and cataract formation. Monitor intraocular pressure regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOTEPREDNOL ETABONATE (LOTEPREDNOL ETABONATE).
| Breastfeeding | Systemic corticosteroids are excreted in human milk. However, due to the minimal systemic absorption of loteprednol etabonate after ocular administration, concentrations in breast milk are likely negligible. The M/P ratio is unknown. Caution is advised when administered to a nursing woman. |
| Teratogenic Risk | Loteprednol etabonate is a pregnancy category C drug. Corticosteroids in general have been associated with increased risk of cleft palate in animal studies and in humans when used in the first trimester. However, loteprednol etabonate is administered topically to the eye, resulting in minimal systemic absorption. Systemic exposure is negligible, and the risk of teratogenicity is considered low. Nevertheless, use during pregnancy should be avoided unless clearly necessary, especially during the first trimester. |
■ FDA Black Box Warning
None.
| Common Effects | Eye irritation Watery eyes Burning sensation |
| Serious Effects |
["Active ocular infections (bacterial, fungal, viral)","Hypersensitivity to loteprednol etabonate or excipients","Epithelial herpes simplex keratitis (dendritic keratitis)"]
| Precautions | ["Prolonged use may increase intraocular pressure (IOP) and risk of glaucoma/cataracts","May mask or exacerbate infections","Not for use in viral (e.g., herpes simplex) or fungal keratitis","Caution in children due to systemic absorption"] |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring is required beyond standard obstetric care. However, if used chronically or at high doses, consider monitoring for signs of adrenal suppression in the mother and infant. |
| Fertility Effects | No specific studies have been conducted on the effects of loteprednol etabonate on human fertility. Topical corticosteroids with minimal systemic absorption are unlikely to impact fertility. Animal studies with corticosteroids have shown reduced fertility at high systemic doses, but such effects are not anticipated with topical ocular use. |